ACIU - AC Immune SA

NasdaqGM - NasdaqGM Real-time price. Currency in USD
2.3000
+0.1200 (+5.50%)
At close: 04:00PM EDT
2.3200 +0.02 (+0.87%)
After hours: 04:04PM EDT
Stock chart is not supported by your current browser
Previous close2.1800
Open2.4600
Bid2.1100 x 3000
Ask2.2800 x 1400
Day's range2.2600 - 2.5300
52-week range1.6800 - 3.9000
Volume144,806
Avg. volume77,946
Market cap192.327M
Beta (5Y monthly)0.58
PE ratio (TTM)N/A
EPS (TTM)-0.9400
Earnings date26 Jul 2023 - 31 Jul 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.65
  • Simply Wall St.

    Here's Why We're Watching AC Immune's (NASDAQ:ACIU) Cash Burn Situation

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

  • Globe Newswire

    AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

    AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease (AD) cohort in ABATE Phase 1b/2 trial;Further ABATE immunogenicity and safety data in higher dose AD cohorts expected in H2 2023 with amyloid-beta-PET imaging data in H1 2024PI-2620 Tau PET tracer pivotal Phase 3 ADvance trial in AD initiated by partner Life Molecular ImagingAD/PD™ 2023 conference featu

  • Simply Wall St.

    AC Immune (NASDAQ:ACIU) shareholders have endured a 76% loss from investing in the stock five years ago

    Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held AC...

  • Globe Newswire

    AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease

    AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease Webinar to take place on Tuesday, April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST Lausanne, Switzerland, April 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, will host a key opinion leader (KOL) webinar on early diagnosis and prevention of Alzheimer’s disease on Tuesday, April 18, 2023 at 10:30 AM EDT

  • Globe Newswire

    AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

    AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline Ten presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM)AC Immune’s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer’s disease Lausanne, Switzerland, March 20, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced

  • Globe Newswire

    AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

    AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update Clinical-stage vaccine programs targeting amyloid-beta (Abeta), phosphorylated-Tau (pTau), and alpha-synuclein (a-syn) are all on track to reach important milestones in 2023ACI-24.060 anti-amyloid-beta vaccine for Alzheimer’s disease (AD) showed positive initial safety and immunogenicity in Phase 1b/2 ABATE trial; further interim data expected in H2 2023; first amyloid plaque PET imaging results anticipated in 2024A

  • Globe Newswire

    AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

    AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023 Lausanne, Switzerland, March 8, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will issue a press release to report its full year 2022 financial results and provide a corporate update on March 16, 2023 at 7:00am ET. Thereafter, Company management will be available for one-on-one ca

  • Globe Newswire

    AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

    AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43 The Michael J. Fox Foundation grant supports the development of AC Immune’s first-in-class TDP-43 PET tracer programTarget ALS Foundation grant supports collaboration between AC Immune and world-class institutions to accelerate the development of novel biofluid assays for detecting TDP-43-related neuropathology Lausanne, Switzerland, February 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharm

  • Globe Newswire

    AC Immune to Present at the SVB Securities Global Biopharma Conference

    AC Immune to Present at the SVB Securities Global Biopharma Conference Lausanne, Switzerland, February 2, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the SVB Securities Global Biopharma Conference, which is taking place virtually from February 14 – 16, 2023. During the fireside chat, AC

  • Zacks

    Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

    Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

  • Globe Newswire

    AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

    AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response in ABATE’s first, low dose cohortACI-24.060 was generally well tolerated with no safety concerns observedWith these findings, dosing in the second, higher dose Alzheimer’s cohort has begunScreening of cohort of study participants with Down syndrome also cleared to beginFurther safety and immunogenic

  • Globe Newswire

    AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

    AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3 trialPI-2620 potentially best-in-class Tau PET tracer with high binding affinity and selectivity for aggregated TauTau accumulation, a key Alzheimer's disease pathology, correlates with cognitive impairment Lausanne, Switzerland, January 18, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharm

  • Simply Wall St.

    AC Immune SA's (NASDAQ:ACIU) largest shareholders are private equity firms with 39% ownership, individual investors own 29%

    A look at the shareholders of AC Immune SA ( NASDAQ:ACIU ) can tell us which group is most powerful. With 39% stake...

  • Globe Newswire

    AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

    AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidateBased on this new clinical data, ACI-35.030 has been selected for further development representing significant progress for the anti-pTau vaccine candidateAC Immune vaccine portfolio targeting three hallmark proteins of neurodegenerative diseases now progressing through advanced clinical development Lausann

  • Simply Wall St.

    Will AC Immune (NASDAQ:ACIU) Spend Its Cash Wisely?

    We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

  • Globe Newswire

    AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

    Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and immunogenicity of ACI-35 and JACI-35, developed in collaboration with Janssen PharmaceuticalsCollaboration partner Genentech/Roche to present pharmacodynamic effects of semorinemab on plasma and CSF Tau biomarkers from “Lauriet” Phase 2 trial in mild-to-moderate Alzheimer’s diseaseBanner Alzheimer’

  • Globe Newswire

    AC Immune to Present at the Jefferies London Healthcare Conference

    LAUSANNE, Switzerland, Nov. 08, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies London Healthcare Conference, which is taking place from November 15 – 17, 2022. During the fireside chat, AC Immune’s CEO Dr. Andrea Pfeifer will provide an overview of the

  • Simply Wall St.

    Shareholders in AC Immune (NASDAQ:ACIU) are in the red if they invested five years ago

    We're definitely into long term investing, but some companies are simply bad investments over any time frame. We don't...

  • Zacks

    AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates

    AC Immune (ACIU) delivered earnings and revenue surprises of 29.17% and 457.95%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Globe Newswire

    AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

    Announced initiation of dosing of anti-Abeta vaccine ACI-24.060 in the biomarker-based Phase 1b/2 ABATE study in patients with prodromal Alzheimer’s disease and individuals with Down syndromeReceived regulatory clearance to initiate an adaptive, biomarker-based Phase 2 study of the anti-alpha-synuclein vaccine ACI-7104 in patients with early Parkinson’s diseasePhase 2 API ADAD study results presented at AAIC 2022 showed numerical differences across multiple endpoints favoring crenezumab anti-Abe

  • Globe Newswire

    AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

    Interim analysis expected around year-end 2022, informing Phase 2 startTrial progressing with regulatory clearances in the UK and also now in SpainPlanned submission of U.S. Investigational New Drug application in Q1 2023Continues progress towards prevention of neurodegenerative diseases LAUSANNE, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today provided an up

  • Globe Newswire

    AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease

    AC Immune’s Tau PET tracer moves closer to becoming a next generation diagnostic for Alzheimer’s Disease (AD)AC Immune to receive a milestone payment from LMI for progress into late-stage product development LAUSANNE, Switzerland, Sept. 26, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that its partner, Life Molecular Imaging (LMI), is moving PI-2620, the Tau positron-

  • Globe Newswire

    AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent

    Previously reported clinical proof-of-concept data on ACI-12589 showed the PET tracer generating the first live images of alpha-synuclein in the human brainNew grant funding will pave the way for enhanced clinical studiesTotal funding from The Michael J. Fox Foundation for AC Immune’s alpha-synuclein PET tracer program is now up to USD 3.7 million LAUSANNE, Switzerland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision

  • Globe Newswire

    AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases

    Vaccines can provide safe, long-lasting immunity, and logistical advantages compared to other treatment modalitiesIntegrating its precision medicine approach, AC Immune is advancing three clinical-stage vaccines targeting Tau, Abeta and α-synucleinPrecisely targeted active immunotherapy may enable prevention of pathological pathways before the occurrence of irreversible neuronal damage LAUSANNE, Switzerland, Aug. 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharm

  • Globe Newswire

    AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases

    Webinar to take place on Wednesday, August 24th at 10:00 AM ET / 4:00 PM CETDiscussion to focus on novel therapeutic approaches and the selection of biomarkers and target proteins for active vaccination approaches LAUSANNE, Switzerland, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will host a key opinion leader (KOL) webinar on vaccinations to treat a